Clearmind Medicine shares rise 14.87% premarket as CMND-100 trial shows favorable safety profile, DSMB recommends continuation.

Clearmind Medicine surged 14.87% in premarket trading following the announcement of pivotal advancements in its CMND-100 clinical trial for Alcohol Use Disorder (AUD). The company, now a clinical-stage entity, reported favorable safety results from its FDA-approved Phase I/IIa trial, including no serious adverse events and DSMB endorsement to continue. This progress, coupled with the activation of multinational trial sites at Yale and Johns Hopkins, signals robust execution. Additionally, the expansion of its IP portfolio to 19 patent families and alignment with industry trends toward non-hallucinogenic neuroplastogens position Clearmind to address high-value metabolic and mental health markets. The CEO’s emphasis on 2025 as a pivotal year and forward-looking data in 2026 further reinforced investor optimism about the drug’s potential to disrupt traditional psychedelic therapies.